Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
Ocular Melanoma, Uveal Melanoma
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Melanoma of the uveal tract (iris, ciliary body, and choroid) is rare, but it is the most common primary intraocular malignancy in adults. The mean age-adjusted incidence of uveal melanoma in the United States is approximately 4.3 new cases per million people, with no clear variation by latitude. The incidence is higher in men (4.9 cases per million) than in women (3.7 cases per million).[1] The age-adjusted incidence of this cancer has remained stable since at least the early 1970s.[1,2] U.S. incidence rates are lower than the rates of other reporting countries, which vary from about 5.3 to 10.9 cases per million. Some of the variation may be the result of differences in inclusion criteria and methods of calculation.[1]
Uveal melanoma is most often diagnosed in older individuals, with a progressively rising, age-specific incidence rate that peaks near age 70 years.[3]
Sources: 3
Host susceptibility factors associated with the development of this cancer include:[2-4]
White race and ethnicity.
Light eye color.
Fair skin.
The ability to tan.
In view of these susceptibility factors, numerous observational studies have explored the relationship between sunlight exposure and risk of uveal melanoma. These studies have found only weak associations or yielded contradictory results.[3] Similarly, there is no consistent evidence that occupational exposure to UV light or other agents is a risk factor for uveal melanoma.[3,5]
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Uveal melanomas can arise in the anterior (iris) or the posterior (ciliary body or choroid) uveal tract.[6] Most uveal tract melanomas originate in the choroid. The ciliary body is a less common site of origin, and the iris is the least common. The comparatively low incidence of iris melanomas has been attributed to the characteristic features of these tumors; they tend to be smaller, slower growing, and relatively dormant compared with their posterior counterparts. Iris melanomas rarely metastasize.[7] Melanomas of the posterior uveal tract generally have a more malignant histological appearance; are detected later; and metastasize more frequently than iris melanomas. The typical choroidal melanoma is a brown, elevated, dome-shaped subretinal mass. The degree of pigmentation ranges from dark brown to totally amelanotic.
Most uveal melanomas are initially completely asymptomatic. As the tumor enlarges, it may cause distortion of the pupil (iris melanoma), blurred vision (ciliary body melanoma), or markedly decreased visual acuity caused by secondary retinal detachment (choroidal melanoma). Serous detachment of the retina may occur. If extensive detachment occurs, secondary angle-closure glaucoma occasionally develops. Clinically, several lesions simulate uveal melanoma, including metastatic carcinoma, posterior scleritis, and benign tumors, such as nevi and hemangiomas.[8]
Sources: 8
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Careful examination by an experienced clinician remains the most important test to diagnose intraocular melanoma. A small uveal melanoma cannot be distinguished from a nevus. Small uveal lesions are observed for growth before making a diagnosis of melanoma. Clinical findings that may help to identify melanoma include:[6]
Sources: 6
Orange pigment on the tumor surface.
Subretinal fluid.
Tumor thickness of more than 2 mm.
Low internal reflectivity on ultrasound examination.
Ancillary diagnostic testing, including fluorescein angiography and ultrasonography, can be extremely valuable in establishing and confirming the diagnosis.[9] In a large, retrospective, single-center series of 2,514 consecutive patients with choroidal nevi, the progression rate to melanoma was 8.6% at 5 years, 12.8% at 10 years, and 17.3% at 15 years.[10]
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Several factors influence prognosis. The most important factors include:
Cell type. For more information, see the Cellular Classification of Intraocular (Uveal) Melanoma section.
Sources: Cellular Classification of Intraocular (Uveal) Melanoma
Tumor size.
Location of the anterior margin of the tumor.
Degree of ciliary body involvement.
Extraocular extension.
Several additional microscopic features can affect the prognosis of intraocular melanoma, including:
Mitotic activity.
Lymphocytic infiltration.
Fibrovascular loops (possibly).
Cell type is the most commonly used predictor of outcome following enucleation. Patients with spindle-A cell melanomas have the best prognosis and patients with epithelioid cell melanomas have the least favorable prognosis.[1,4,9] Nevertheless, most tumors have an admixture of cell types, and there is no clear consensus regarding the proportion of epithelioid cells that constitutes designation of a tumor as mixed or epithelioid.[6]
Extraocular extension, recurrence, and metastasis are associated with an extremely poor prognosis, and long-term survival cannot be expected for patients with these features.[11] The 5-year mortality rate for patients with metastasis from ciliary body or choroidal melanoma is approximately 30%, compared with a rate of 2% to 3% for patients with iris melanomas.[12]
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Patients with iris melanomas have relatively good outcomes, with 5-year survival rates exceeding 95%. Iris melanomas are predominantly of the spindle-cell type and are usually smaller in size than posterior melanomas because they are detected earlier. Conservative management is generally advocated whenever possible, but surgical intervention may be justified with unequivocal tumor growth or with extensive disease at initial examination.
The management of small choroidal melanomas is controversial, and it is not clear whether treating small tumors prevents metastasis.[1] The natural history of small choroidal melanomas is poorly understood. Small, pigmented, choroidal lesions cannot always be differentiated reliably on examination. Growth is a presumed indicator of malignant potential.[2] The likelihood of progression from the time of diagnosis to the time when tumor growth warrants treatment has not been well characterized. Some ophthalmologists advocate observation. This course has been justified on several grounds, including the difficulty of establishing a correct diagnosis, the lack of any documented efficacy for globe-conserving treatments, and concerns for severe treatment-related morbidity. Others have advocated earlier therapeutic intervention.[1,3,4]
Although patients diagnosed with small choroidal tumors were not eligible for participation in the Collaborative Ocular Melanoma Study (COMS), these patients could participate in a prospective follow-up study to evaluate the natural history of small lesions. The 2-year tumor growth estimates were 21%, and the 5-year tumor growth estimates were 31%.[5] Clinical risk factors associated with tumor growth included:[3,5]
Increased tumor thickness.
Presence of subretinal fluid.
Orange pigmentation.
Absence of drusen.
Absence of retinal pigment.
Margin at the optic disc.
Epithelial changes surrounding the tumor.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
The selection of treatment depends on the following:
Site of origin (choroid, ciliary body, or iris).
Size and location of the lesion.
Age of the patient.
Occurrence of extraocular invasion, recurrence, or metastasis.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
In the past, enucleation (eye removal) was the standard treatment for primary choroidal melanoma, and it is still used when large tumors are present. However, enucleation has been largely replaced by radiation therapy (i.e., brachytherapy with radioactive plaques or external-beam, charged-particle radiation therapy) to spare the affected eye.[6,7]
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
A randomized trial evaluated the role of pre-enucleation EBRT for large choroidal tumors that required enucleation. The study found that EBRT had no impact on overall survival (OS).[8,9][Level of evidence A1] A COMS trial included 1,003 patients with large choroidal melanomas (≥2 mm in height and ≥16 mm in diameter, or ≥10 mm in height irrespective of diameter, or ≥8 mm in height and border <2 mm from the optic disc) with no known metastases. Patients were randomly assigned to receive enucleation alone or enucleation after preoperative external photon-beam radiation from cobalt 60 or accelerators (20 Gy in 5 daily fractions) to the orbit and globe.[8,9] Through 10 years of follow-up, the median survival in both arms was approximately 7 years, and the 10-year all-cause mortality rate was 61% in both arms (relative risk [RR]death, 1.00; 95% confidence interval [CI], 0.85–1.18). Metastasis-free survival was also nearly identical in both arms.
Sources: 8 · 9 · Level of evidence A1 · 8 · 9
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Eye-sparing transscleral local resection plays a limited role in the management of uveal melanoma. It is used in patients with large choroidal and ciliary body tumors who are not candidates for radiation therapy but are highly motivated to retain their eye.[10-12] The procedure is technically demanding and is generally performed only in centers with specialized expertise in this surgery. There is a substantial risk of retinal detachment, intraocular bleeding, and complications associated with the anesthesia-induced hypotension used to decrease the risk of bleeding. Either adjuvant brachytherapy or neoadjuvant proton-beam therapy are administered. Experience is limited to retrospective, single-center, case series.[10-12][Level of evidence C3]
Sources: 10 · 12 · 10 · 12 · Level of evidence C3
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Surgical resection of metastases from ocular melanoma has been reported in case series of highly selected patients with occasional favorable outcomes.[13,14] However, the favorable outcomes may be the result of strong patient-selection factors, and the role of resection in this setting is unclear.[13,14][Level of evidence C3]
Sources: 13 · 14 · 13 · 14 · Level of evidence C3
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Episcleral brachytherapy using plaques containing small radioactive seeds is the most common form of radiation used in the management of intraocular melanoma. Iodine I 125 (125I), cobalt Co 60 (60Co), palladium Pd 103 (103Pd), iridium Ir 192 (192Ir), and ruthenium Ru 106 (106Ru) are examples of radioactive isotopes used in the brachytherapy plaques. Isotopes with relatively low photon and electron emissions (125I, 103Pd, and 106Ru) are more easily shielded to reduce the exposure to adjacent normal tissues, and 125I is probably the most commonly used radioisotope.[15] Although plaque radiation therapy allows preservation of the eye, visual acuity is frequently lost over time.
Sources: 15
In a case series of 1,106 patients who were treated with plaque radiation therapy for uveal melanoma and who had an initial acuity of at least 20/100, 68% developed poor acuity (i.e., 20/200 or worse) within 10 years.[16]
Sources: 16
Factors associated with worse acuity outcomes included:[16]
Sources: 16
Age older than 60 years.
Diminished baseline acuity.
Diabetes.
Increased tumor size and thickness.
Location near the fovea or optic disc.
Type of isotope therapy (106Ru, 60Co, or 192Ir vs. 125I).
125I brachytherapy yields equivalent overall and melanoma metastasis-specific survival rates to enucleation for medium-sized melanomas.[17][Level of evidence A1] The randomized COMS Medium Tumor Trial compared 125I episcleral-plaque brachytherapy (85 Gy at 0.42–1.06 Gy/hr) with enucleation in 1,317 patients with medium-sized choroidal tumors (tumor height 2.5–10.0 mm and tumor diameter ≤16.0 mm that were not contiguous with the optic disc).[17] Eighty-five percent of the patients treated with 125I brachytherapy retained their eye for 5 years or more, and 37% of them had visual acuity better than 20/200 in the irradiated eye 5 years after treatment.[17] No statistically significant differences in mortality were observed between the two study arms after 12 years of follow-up, either for death from all causes or death with histopathologically confirmed melanoma metastasis.[18] The 5- and 10-year all-cause mortality rates were 19% and 35% in both study arms. The cumulative all-cause mortality rate at 12 years was 43% in the 125I arm versus 41% in the enucleation arm (RR, 1.04; 95% CI, 0.86–1.24). The 5-year metastasis-specific mortality rates were 13% in both arms; at 10 years, the rates were 21% and 22% (RR for metastasis-specific mortality, 1.07; 95% CI, 0.81–1.41 through 12 years).
Sources: 17 · Level of evidence A1 · 17 · 17 · 18
In a companion study within the COMS, 209 patients were prospectively assessed for quality of life during the first 5 years of follow-up.[19] Both study groups reported increasing difficulty with vision-oriented daily activities and ocular pain as time elapsed. Most measures of visual function were similar between the two groups. However, there were statistically significant differences favoring the brachytherapy group in comfort with driving for the first year after therapy and in reported peripheral vision for the first 2 years after therapy. These differences disappeared by year 5 of follow-up.[19][Level of evidence A3]
Sources: 19 · 19 · Level of evidence A3
Charged-particle EBRT (using protons, carbon ions, or helium ions) is the other major form of radiation therapy used in the management of ocular melanomas.[20-23] This form of radiation therapy requires sophisticated equipment available only at selected centers. In addition, charged-particle EBRT involves patient cooperation during treatment (e.g., voluntarily fixating the eye on a particular point so the tumor is positioned properly in the radiation beam). A lower risk of early and late local radiation failures has been reported after charged-particle EBRT than after the use of brachytherapy, possibly resulting from differences in dose distribution in the two techniques.[20][Levels of evidence B3 and C3]
In a single-center, single-surgeon study, 184 patients with uveal melanomas smaller than 15 mm in diameter and smaller than 10 mm in thickness were randomly assigned to receive 125I brachytherapy versus helium ion radiation (to an estimated dose of 70 Gy equivalents in 5 fractions over 7 to 11 days in each arm).[24] The local tumor regrowth rate by 4 years was 13.3% in the brachytherapy arm compared with 0% in the helium ion arm (P < .001). However, the rates of metastasis, death from metastasis, and overall mortality were similar in both arms.[24][Level of evidence B3]
Sources: 24 · 24 · Level of evidence B3
Because of its dose distribution, charged-particle irradiation can be better used than plaque brachytherapy to treat larger tumors and tumors closer to the fovea or optic disc. A large, single-center, single-surgeon series of 2,069 patients treated with proton-beam therapy had an actuarial local control rate of 95% (95% CI, 93%–96%) at 15 years. The cumulative rate of enucleation was 16% (95% CI, 13%–20%). Enucleations were primarily the result of neovascular glaucoma (46% of enucleations), blind uncomfortable eyes (31% of enucleations), or local recurrence (23% of enucleations). As with plaque radiation, risk factors for deterioration in visual acuity after charged-particle radiation were tumor size, location near the fovea or optic disc, baseline acuity, and underlying diabetes.[21]
Sources: 21
Similarly, another large, single-center, single-surgeon, consecutive series of 886 patients treated with proton-beam irradiation reported a local control rate of 92.1% (95% CI, 89.8%–94.6%) and ocular conservation rate of 87.3% (95% CI, 83.9%–90.9%) at 10 years.[22][Level of evidence C3] The actuarial OS rate at 10 years was 64.1% (95% CI, 59.5%–69.0%).
Sources: 22 · Level of evidence C3
In a single-center, phase I/II study of 57 evaluable patients treated with carbon ion-beam irradiation and followed for a median of 26 months, 26 patients developed neovascular glaucoma or severe eye pain from increased intraocular pressure, and 3 patients underwent enucleation. One patient had a local tumor recurrence.[23]
Sources: 23
In an attempt to lower the complication rate and improve functional outcomes, one study compared a decreased dose of 50 cobalt Gy equivalents (CGE) with 70 CGE proton beam (each delivered in 5 fractions, usually within a 7-day period). Patients (n = 188) with tumors smaller than 15 mm in diameter and smaller than 5 mm in height, which were located near the optic disc or macula, were randomly assigned to the two doses in a double-masked study design. At 5 years, there were no statistically significant differences in local tumor control, rate of metastasis, visual acuity, or complication rates. However, the visual fields were better in the 50-CGE group.[25][Level of evidence B3]
Sources: 25 · Level of evidence B3
As noted in the Surgery section, the role of pre-enucleation external photon-beam radiation therapy has been tested in a randomized trial and has shown no impact on OS for large choroidal tumors treated with enucleation.[8,9]
External-beam–photon-beam (gamma-ray) radiation therapy with gamma-knife stereotactic radiation surgery as a single-fraction [26] or fractionated stereotactic radiation [27,28] is being investigated as an alternative to brachytherapy or charged-beam radiation for posterior uveal melanomas, particularly for tumors too large or too close to the optic disc or macula to treat with brachytherapy. Because the dose rate of radiation has a slower delivery time than is the case with charged particles, specialized techniques are used to immobilize the eye [26] or to avoid delivery of the photons while the eye is moving or closed.[28] Experience is more limited with external-beam–photon therapy than for either brachytherapy or charged-particle EBRT, and there are no controlled comparisons with either of the other techniques. Early results from single-center series suggest similar levels of local tumor control and eye retention rates, but patient-selection factors may play a role.[28][Level of evidence C3]
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Transpupillary thermotherapy (TTT) directs an infrared laser, usually at a wavelength of 810 nm, through a dilated pupil in one or more sessions to induce heat necrosis of uveal melanomas. This method carries the theoretical advantage of high-precision destruction of tumor tissue under direct visualization. However, TTT has important limitations that confine its use to specific circumstances.[1,29] The limited ability of TTT to penetrate thick tumors with sufficient energy restricts its use to small melanomas or tumors of a size that some ophthalmologists recommend for follow-up without any initial therapy. For more information, see the Observation section. When used as the primary therapy, there are relatively high rates of local recurrence and retinal vascular damage. Recurrence rates are particularly high when the tumor abuts the optic nerve and overhangs the optic disc.[1][Level of evidence C3]
Sources: 1 · 29 · Observation · 1 · Level of evidence C3
In a single-center study, 95 patients with small choroidal melanomas (diameter <10 mm and thickness <3.5 mm) were randomly assigned to receive either TTT or 125I brachytherapy (100 Gy).[30] The tumor regression rate was 92% in the TTT arm and 98% in the 125I arm (P = .4). With a mean follow-up time of 56.2 months, there were four recurrences in the TTT arm and one in the 125I arm. However, the study was too small to provide clear information on efficacy differences.
Sources: 30
TTT is also under evaluation as an adjunct to primary therapy with proton-beam radiation. In large uveal melanomas, proton-beam therapy is associated with exudative, inflammatory, and glaucomatous complications that may require enucleation. In a single-center trial, 151 patients with uveal melanomas at least 7 mm thick or at least 15 mm in diameter were randomly assigned to receive proton-beam radiation (60 CGEs over four daily fractions) with or without TTT (810 nm wavelength at 1, 6, and 12 months after therapy) and followed for a median of 38 months.[31] There were no differences between the two groups in maculopathy, papillopathy, or glaucoma. The enucleation rate was lower in the TTT group (about 2% vs. 18% at 5 years, P = .02). However, the study was not masked, and replication of the results would be important.
Sources: 31
There are uncertainties at all stages about the optimal management of intraocular melanoma. Physicians should discuss clinical trial opportunities with eligible patients. Information about ongoing clinical trials is available from the NCI website.
Sources: NCI website
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Melanocytic stromal proliferations and nevi of the iris are the most common tumors of the iris, but melanoma is rare.[1,2] Clinical differentiation between an iris nevus and a melanoma might sometimes be difficult and, at times, impossible. Melanomas of the iris are usually small discrete lesions, although they may occasionally be diffuse, infiltrative, or multiple and may result in heterochromia, chronic uveitis, or spontaneous hemorrhage into the anterior chamber of the eye (hyphema). Iris melanomas that involve more than 66% of the angle circumference are associated with secondary glaucoma.[3]
Routine evaluation of iris melanomas includes gonioscopy, transillumination of the globe, and indirect ophthalmoscopy with 360° of scleral depression. Photographic documentation is essential to verify progression in size or growth of the tumor.[4] Anterior segment fluorescein angiography may be helpful to demonstrate the vascularity of the lesion but is not diagnostic. High-resolution ultrasound biomicroscopy can be used to measure small lesions (basal dimensions and thickness) and to assess tumor involvement of the anterior ciliary body, angle, and overlying sclera.[5] The main disadvantage with this technology is its limited penetration of large lesions. In these cases, conventional ultrasonography is more accurate.
In general, patients with iris melanomas have relatively good outcomes. Only about 3% of these melanomas metastasize within 5 years.[1] Iris melanomas are predominantly of the spindle-cell type and are usually smaller in size than posterior melanomas. Clinical features, including prominent tumor vascularity, rapid growth, and heterogeneous pigmentation, are associated with an epithelioid cell component.[6] Involvement of the iridocorneal angles is frequently associated with ciliary body invasion.[6]
Because iris melanomas are rare and have a good prognosis, clinical trials with sufficient power are impractical. Therefore, treatment experience is based principally on case series and case reports. Conservative management is generally advocated whenever possible, but surgical intervention may be justified with unequivocal tumor growth or extensive disease at initial examination.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment options for iris melanoma include:
Observation with careful follow-up. This option is used in asymptomatic patients with stable lesions; follow-up includes serial photography.[3]
Sources: 3
Local resection. This option is used when progressive and pronounced growth is documented.[2]
Sources: 2
Enucleation. This option is used if the tumor is not amenable to local resection because of diffuse involvement of the iris, involvement of more than 50% of the iris and anterior chamber angle, intractable glaucoma, or extraocular extension.[7]
Sources: 7
Plaque radiation therapy. This option is offered as an alternative for large, diffuse, surgically nonresectable lesions of the iris.[8]
Sources: 8
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Melanoma involving the ciliary body is rare and patients have a poor prognosis. In some cases, diagnosis may be difficult because of similarity to other eye diseases. The differential diagnosis of ciliary body melanoma is considered in cases of unilateral pigmentary glaucoma and chronic uveitis.[1]
Sources: 1
Ultrasound biomicroscopy can be used to evaluate tumor shape, thickness, margins, reflectivity, and local invasion.[2,3] Patients with tumors greater than 7 mm in thickness are at increased risk of metastatic disease and melanoma-related death compared with patients with thinner tumors.[4]
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
There are several options for management of ciliary body melanoma. All of them are reported from case series.[Level of evidence C3] The choice of therapy, however, depends on many factors.
Sources: Level of evidence C3
Treatment options for ciliary body melanoma include:
Plaque radiation therapy. Local control rates are high, but treatment is associated with a high incidence of secondary cataract.[4,5]
External-beam, charged-particle radiation therapy. This approach is offered at specialized referral centers. It requires careful patient cooperation, with voluntary fixation of gaze.[6-8]
Local tumor resection. This option is mainly suitable for selected ciliary body or anterior choroidal tumors with smaller basal dimension and greater thickness.[9,10]
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
A wide range of 5-year mortality rates has been reported for patients with small choroidal melanomas, with an average rate of about 16%.[1,2] Several studies indicate that the two most important clinical factors predictive of mortality are larger tumor size at the time of treatment and documentation of tumor growth.[3]
The management of small choroidal melanomas is controversial. The likelihood of progression from the time of diagnosis to growth warranting treatment has not been well characterized. Many ophthalmologists advocate initial observation. This initial management strategy is justified on several grounds, including difficulty in establishing a correct diagnosis, lack of documented efficacy for globe-conserving treatments, and concerns for severe treatment-related morbidity. Others have advocated earlier therapeutic intervention.[4-6]
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Treatment options for small choroidal melanoma include:
Observation. This strategy is important for patients with an uncertain diagnosis or whose tumor growth has not been documented. It is also used for asymptomatic patients with stable lesions (particularly older or debilitated patients) and for patients with a tumor in their only useful eye.[2]
Sources: 2
Plaque radiation therapy. This treatment is used for small- or medium-sized uveal melanomas, amelanotic tumors, or tumors that touch the optic disc for greater than 3 clock-hours of optic disk circumference.[7,8]
External-beam, charged-particle radiation therapy. This approach is offered at specialized referral centers. It requires careful patient cooperation, with voluntary fixation of gaze.[7-10]
Gamma-knife radiation surgery. This treatment may be a feasible option for small- to medium-sized melanomas.[11-13]
Transpupillary thermotherapy. As noted above, this approach has very limited use, but it can be used as a primary treatment or as an adjunctive method to plaque radiation therapy.[5,6,14-18] For more information, see the Transpupillary Thermotherapy section.
Sources: 5 · 6 · 14 · 18 · Transpupillary Thermotherapy
Local tumor resection. This strategy is used mainly for selected ciliary body or anterior choroidal tumors with smaller basal dimensions and greater thickness.[19]
Sources: 19
Enucleation. This approach is used when severe intraocular pressure elevation is a factor. It may also be considered with small- and medium-sized melanomas that are invading the tissues of the optic nerve.[20]
Sources: 20
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Eye-sparing radiation therapy, either by plaque brachytherapy or external beam, is the preferred option for most patients with medium-sized choroidal melanoma. Enucleation remains the standard therapy for large choroidal melanomas and melanomas that cause severe glaucoma or invade the optic nerve.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Tumor growth pattern is a factor in the therapeutic decision. Enucleation is considered for a diffuse melanoma or extraocular extension, but radiation therapy can be employed for less extensive disease.
Treatment options for medium and large choroidal melanoma include:
Medium-sized choroidal melanomas
External-beam, charged-particle radiation therapy. This approach is offered at specialized referral centers. It requires careful patient cooperation, with voluntary fixation of gaze.[5-7]
Combined therapy, with ablative laser coagulation or transpupillary thermotherapy to supplement plaque treatment.[10,11] For more information, see the Transpupillary Thermotherapy section.
Sources: 10 · 11 · Transpupillary Thermotherapy
Enucleation. This approach is considered primarily for diffuse melanomas or extraocular extension. Enucleation may be necessary when there are radiation complications or tumor recurrences.[10]
Sources: 10
Large choroidal melanomas
Enucleation when the tumor is judged to be too large for eye-sparing approaches.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
Extrascleral extension is associated with a poor prognosis. For patients with gross tumor involvement of the orbit, treatment requires orbital exenteration. However, there is no evidence that such radical surgery will prolong survival. Most patients with localized or encapsulated extraocular extension are not exenterated. This subject is controversial.[1-5]
No effective method of systemic treatment has been identified for patients with metastatic ocular melanoma. Clinical trials are an option for these patients.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 16, 2025. Captured 2026-09-09.
The prognosis for any patient with recurring or relapsing disease is poor, regardless of cell type or stage. The question and selection of further treatment depends on many factors, including the extent of the lesion, age and health of the patient, prior treatment, site of recurrence, and individual patient considerations. Surgical resection of metastases diagnosed after initial management of ocular melanoma in single-center case series of highly selected patients has been reported. The extent to which the occasional favorable outcomes are the result of strong selection factors is not clear, so this approach cannot be considered standard.[1]
Sources: 1
Eligible patients should consider participation in clinical trials whenever possible.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
The prognosis and treatment options depend on:
How the melanoma cells look under a microscope.
Sources: melanoma
The size and thickness of the tumor.
Whether the tumor is in the iris, ciliary body, or choroid part of the eye.
Whether the tumor has spread within the eye or to other places in the body.
Whether there are certain changes in the genes linked to intraocular melanoma.
Sources: genes
The patient's age and general health.
Whether the tumor has recurred (come back) after treatment.
Sources: recurred
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
The tumor is 5 to 16 millimeters in diameter and from 1 to 3 millimeters thick.
Sources: millimeters · diameter
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
The tumor is 16 millimeters or smaller in diameter and from 3.1 to 8 millimeters thick.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
The melanoma may come back in the eye or in other parts of the body.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
There are different types of treatment for patients with intraocular melanoma.
The following types of treatment are used:
The following types of treatment are used:
Surgery
Watchful waiting
Radiation therapy
Photocoagulation
Thermotherapy
New types of treatment are being tested in clinical trials.
Treatment for intraocular (uveal) melanoma may cause side effects.
Patients may want to think about taking part in a clinical trial.
Patients can enter clinical trials before, during, or after starting their cancer treatment.
Follow-up care may be needed.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Different types of treatment are available for patients with intraocular melanoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.
Sources: intraocular melanoma · standard · clinical trials · research study
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Surgery is the most common treatment for intraocular melanoma. The following types of surgery may be used:
Resection: Surgery to remove the tumor and a small amount of healthy tissue around it.
Sources: tumor
Enucleation: Surgery to remove the eye and part of the optic nerve. This is done if vision cannot be saved and the tumor is large, has spread to the optic nerve, or causes high pressure inside the eye. After surgery, the patient is usually fitted for an artificial eye to match the size and color of the other eye.
Sources: optic nerve
Exenteration: Surgery to remove the eye and eyelid, and muscles, nerves, and fat in the eye socket. After surgery, the patient may be fitted for an artificial eye to match the size and color of the other eye or a facial prosthesis.
Sources: nerves · eye socket · prosthesis
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Watchful waiting is closely monitoring a patient’s condition without giving any treatment until signs or symptoms appear or change. Pictures are taken over time to keep track of changes in the size of the tumor and how fast it is growing.
Sources: Watchful waiting · monitoring · signs · symptoms
Watchful waiting is used for patients who do not have signs or symptoms, and the tumor is not growing. It is also used when the tumor is in the only eye with useful vision.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:
Sources: Radiation therapy · x-rays · radiation · cells
External radiation therapy uses a machine outside the body to send radiation toward the cancer. Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. These types of external radiation therapy include:
Sources: External radiation therapy
External radiation therapy uses a machine outside the body to send radiation toward the cancer. Certain ways of giving radiation therapy can help keep radiation from damaging nearby healthy tissue. These types of external radiation therapy include:
Charged-particle external-beam radiation therapy is a type of external-beam radiation therapy. A special radiation therapy machine aims tiny, invisible particles, called protons or helium ions, at the cancer cells to kill them with little damage to nearby normal tissues. Charged-particle radiation therapy uses a different type of radiation than the x-ray type of radiation therapy.
Sources: Charged-particle external-beam radiation therapy · protons · ions
Gamma Knife therapy is a type of stereotactic radiosurgery used for some melanomas. This treatment can be given in one treatment. It aims tightly focused gamma rays directly at the tumor so there is little damage to healthy tissue. Gamma Knife therapy does not use a knife to remove the tumor and is not an operation.
Sources: Gamma Knife therapy · stereotactic radiosurgery · melanomas · gamma rays
Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer. Certain ways of giving radiation therapy can help keep radiation from damaging healthy tissue. This type of internal radiation therapy may include:
Sources: Internal radiation therapy · radioactive · seeds · catheters
Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer. Certain ways of giving radiation therapy can help keep radiation from damaging healthy tissue. This type of internal radiation therapy may include:
Localized plaque radiation therapy is a type of internal radiation therapy that may be used for tumors of the eye. Radioactive seeds are attached to one side of a disk, called a plaque, and placed directly on the outside wall of the eye near the tumor. The side of the plaque with the seeds on it faces the eyeball, aiming radiation at the tumor. The plaque helps protect other nearby tissue from the radiation.
Sources: Localized · plaque radiation therapy
The way the radiation therapy is given depends on the type and stage of the cancer being treated. External and internal radiation therapy are used to treat intraocular melanoma.
Sources: stage
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Photocoagulation is a procedure that uses laser light to destroy blood vessels that bring nutrients to the tumor, causing the tumor cells to die. Photocoagulation may be used to treat small tumors. This is also called light coagulation.
Sources: laser · blood vessels · nutrients
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Thermotherapy is the use of heat from a laser to destroy cancer cells and shrink the tumor.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Information about clinical trials is available from the NCI website.
Sources: NCI website
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
For information about side effects caused by treatment for cancer, visit our Side Effects page.
Sources: side effects · Side Effects
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.
Sources: clinical trial · standard treatment
Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.
Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.
Sources: side effects
Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trials search · ClinicalTrials.gov
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
For information about the treatments listed below, see the Treatment Option Overview section.
Sources: Treatment Option Overview
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Watchful waiting.
Sources: Watchful waiting
Surgery (resection or enucleation).
Sources: resection · enucleation
Plaque radiation therapy, for tumors that cannot be removed by surgery.
Sources: Plaque radiation therapy · tumors
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Treatment of ciliary body melanoma may include:
Sources: ciliary body · melanoma
Plaque radiation therapy.
Sources: Plaque radiation therapy
Charged-particle external-beam radiation therapy.
Surgery (resection or enucleation).
Sources: resection · enucleation
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Watchful waiting.
Sources: Watchful waiting
Plaque radiation therapy.
Sources: Plaque radiation therapy
Charged-particle external-beam radiation therapy.
Gamma Knife therapy.
Sources: Gamma Knife therapy
Thermotherapy.
Sources: Thermotherapy
Surgery (resection or enucleation).
Sources: resection · enucleation
Treatment of medium choroid melanoma may include:
Plaque radiation therapy with or without photocoagulation or thermotherapy.
Sources: photocoagulation
Charged-particle external-beam radiation therapy.
Surgery (resection or enucleation).
Treatment of large choroid melanoma may include:
Enucleation when the tumor is too large for treatments that save the eye.
Sources: tumor
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
Treatment of extraocular extension melanoma that has spread to the bone around the eye may include:
Sources: extraocular · melanoma
Surgery (exenteration).
Sources: exenteration
A clinical trial.
Sources: clinical trial
An effective treatment for metastatic intraocular melanoma has not been found. A clinical trial may be a treatment option. Talk with your doctor about your treatment options.
Sources: metastatic · intraocular melanoma
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 14, 2025. Captured 2026-09-09.
An effective treatment for recurrent intraocular melanoma has not been found. A clinical trial may be a treatment option. Talk with your doctor about your treatment options.
Sources: recurrent · intraocular melanoma · clinical trial
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Ocular Melanoma, Uveal Melanoma
ClinicalTrials.gov recordUveal Melanoma
ClinicalTrials.gov recordMesothelioma, Uveal Melanoma, Renal Cell Carcinoma, Cholangiocarcinoma
ClinicalTrials.gov recordHEPZATO is an alkylating drug indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease...
1 INDICATIONS AND USAGE HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the...
Intraocular (Uveal) Melanoma
KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma ( 1 , 2.1 ).
Treatment of Extraocular Extension and Metastatic Intraocular Melanoma
Treatment of Recurrent Intraocular Melanoma
HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic...
DailyMed labelKIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of...
DailyMed label